Sharechat Logo

Abano extends Wellington pathology contract by a year in $26 mln deal

Thursday 17th October 2013

Text too small?

Abano Healthcare, the specialist medical investor facing a takeover bid from interests associated with its biggest shareholder, has extended its contract to provide Wellington district health boards with pathology services for another year.

Aotea Pathology has extended its contract with the Hutt Value and Capital & Coast district health boards until October 2015 in a deal worth just over $26 million, Abano said in a statement. The extension will give the DHBs some room to review their services as they look for the most cost-efficient means to source pathology and lab services in the region.

"The DHB review is important to ensure that there continues to be a professional, high quality medical service for the greater Wellington area, which provides best value for money," Abano managing director Alan Clarke said. "We hope that this may lead to longer term contract tenure which would be to the benefit of all parties."

The Abano unit got a three-year extension in 2010 worth $75 million. The locally-listed company holds a 55 percent controlling stake in Aotea Pathology, with the remainder held by Sonic Healthcare.

Abano shares were unchanged at $6.76 in trading today.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors